Modality
ERT
MOA
MDM2i
Target
SGLT2
Pathway
PD-1/PD-L1
FTDGastric CaEoE
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
~Dec 2020
→ ~Mar 2022
Phase 2
~Jun 2022
→ ~Sep 2023
Phase 3
Dec 2023
→ Jan 2030
Phase 3Current
NCT07894035
2,626 pts·FTD
2024-07→2027-10·Not yet recruiting
NCT06035217
1,432 pts·FTD
2023-12→2030-01·Recruiting
4,058 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-141.5y awayPh3 Readout· FTD
2030-01-153.8y awayPh3 Readout· FTD
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P3
Recruit…
P3
Not yet…
Catalysts
Ph3 Readout
2027-10-14 · 1.5y away
FTD
Ph3 Readout
2030-01-15 · 3.8y away
FTD
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07894035 | Phase 3 | FTD | Not yet recr... | 2626 | EDSS |
| NCT06035217 | Phase 3 | FTD | Recruiting | 1432 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 |